Systematic Review and Meta-analysis of the Effectiveness and Safety of Hydroxychloroquine in COVID-19.

Tzu-Han Yang^{1,a}, Chian-Yin Chou^{1,2,a}, Yi-Fan Yang³, Yi-Ping Yang^{4,5}, Chian-Shiu Chien^{4,5}, Aliaksandr A. Yarmishyn^{4,5}, Tzu-Ying Yang⁶, Shih-Hwa Chiou^{4,5}, Yuh-Lih Chang^{1,2,7}

Taiwan.

All authors take responsibility for all aspects of the reliability and freedom from bias of NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

¹ Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan.

² Faculty of Pharmacy, School of Pharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan.

³ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

⁴ Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan.

⁵ Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan

⁶ Department of dietetics and nutrition, Taipei Veterans General Hospital, Taipei,

Department and Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan.

^a Both authors contributed equally

the data presented and their discussed interpretation.

Correspondence: Dr. Yuh-Lih Chang, Department of Pharmacy, Taipei Veterans

General Hospital, 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan

(ylchang@vghtpe.gov.tw).

Declaration of interest: The authors report no conflict of interest.

Keywords: COVID-19; SARS-CoV-2; hydroxychloroquine; azithromycin; systematic

review.

Paper length: 3779 words

Title word count: 13

Abstract word count: 248

Take home: This study demonstrates that the use of hydroxychloroquine with or without

azithromycin might have benefits in positive-to-negative conversion of SARS-CoV-2 and

reduction of progression rate, but was associated with increased mortality in COVID-19.

Running title: Hydroxychloroquine for treating COVID-19

Abstract.

Backgrounds.

Since COVID-19 outbreak, various agents have been tested but no proven effective

therapies have been identified. This has led to a lot of controversies among associated

researches. Hence, in order to address the issue of using hydroxychloroquine in treating

COVID-19 patients, we conducted a systematic review and meta-analysis.

Methods.

A thorough search was carried out to find relevant studies in MEDLINE, medRxiv,

PubMed, Cochrane Database, China Academic Journals Full-text Database and Web of

Science. Two investigators independently reviewed 274 abstracts and 23 articles. The

trials which evaluated hydroxychloroquine for treatment of COVID-19 were included for

this systematic review. Two investigators assessed quality of the studies and data

extraction was done by one reviewer and cross checked by the other.

Results.

Five trials involving 677 patients were included while conducting the meta-analysis.

Compared with the control group, hydroxychloroquine with or without azithromycin

showed benefits in positive-to-negative conversion of SARS-CoV-2 (odds ratio [OR],

1.95 [95% CI,0.19 to 19.73] and a reduction in progression rate (OR, 0.89 [95% CI, 0.58

to 1.37]), but without demonstrating any statistical significance. This systematic review

has also suggested a possible synergistic effect of the combination therapy which included

hydroxychloroquine and azithromycin. However, the use of hydroxychloroquine alone

was associated with increased mortality in COVID-19 patients.

Conclusion.

The use of hydroxychloroquine with or without azithromycin for treatment of COVID-

19 patients, seems to be effective. The combination of hydroxychloroquine and

azithromycin has shown synergic effects. However, mortality rate was increased when

the treatment was conducted with hydroxychloroquine.

Keywords.

COVID-19; SARS-CoV-2; hydroxychloroquine; azithromycin; systematic review

INTRODUCTION

In December 2019, the sudden outbreak of newly detected coronavirus (SARS-CoV-2) resulted in spread of coronavirus disease (COVID-19) to other countries, leading to a global pandemic. This virus was initially reported in the Hubei province, Wuhan, China [1]. As of April 27, 2020, more than 3 million people have been rapidly affected by COVID-19 worldwide and over two hundred thousand people have died in more than 200 countries due to this deadly disease [2]. As COVID-19 is spreading at a fast pace therefore without wasting time researchers are working tirelessly to find an effective treatment for this disease. However, despite all the efforts there is no proven, effective,

pharmacological treatment available currently except following infection control and

preventive strategies such as personal protective measures and social distancing,.

Various active clinical trials are underway to detect effectiveness of ribavirin, remdesivir, lopinavir/ritonavir and hydroxychloroquine for COVID-19 treatment. The pathogenic mechanisms of SARS-CoV-2 might be related to its impact on immune system since SARS-CoV-2 can infect T cells [3]. Therefore, recently conducted studies have drawn a lot of attention to the possible benefit of hydroxychloroquine, an antimalarial agent with an immunomodulatory activity which has been used at a large-scale for the treatment of rheumatic disease mainly because of its relatively low price and considerable safety.

Colson et al. has speculated that hydroxychloroquine might be the choice in treating COVID-19 patients [4]. Some vitro studies have demonstrated that inhydroxychloroquine has a potent antiviral activity against SARS-CoV-2 [5, 6]. Based on the outcome seen in some in vitro studies, numerous clinical studies were launched but only few of these which were published, presented relevant results and highlighted the efficacy of different treatment modalities [7-15]. Additionally, a lot of controversial findings are noticed among the researches. A study conducted by Gautret et al. has supported that hydroxychloroquine is effective in reducing viral load [8], while there are a few studies which disagree with this [7]. Some research studies have even reported harmful effects of hydroxychloroquine [10, 16]. Moreover, most of the published studies had small sample size [7-9, 13] or conducted a non-randomized clinical trial (non-RCT), which are major limitations in deriving a sound outcome [8, 10-12, 14, 15]. Many review articles which have discussed the use of hydroxychloroguine in COVID-19 patients showed limitation as they included only few relevant studies, significant Chinese studies were omitted and analysis of treatment effects was not quantified while formulating the results [17-19]. Recently, two systematic review with meta-analysis were published which had small sample size [20] and there was no clear clarity with regard to the effects of using hydroxychloroquine alone, or when combined with azithromycin, for the treatment of COVID-19 [21]. These systematic review did not include any national trials

and also excluded population of non-Hispanic black while conducting their research [20,

21].

On April 24, FDA issued a warning against use of hydroxychloroquine and chloroquine

for treating patients with COVID-19 due to its serious adverse effect, such as heart

arrhythmias being reported in some patients. Therefore, efficacy and safety of

hydroxychloroquine for patient with COVID-19 is still uncertain. In view of severe

outbreak of COVID-19 and rapid increase of studies being conducted, it is crucial to

systematically evaluate the relevant studies in a rigorous manner. Hence, we conducted a

systematic review and meta-analysis to demonstrate the significance of present evidence

regarding benefits and safety of hydroxychloroquine use, for the treatment of COVID-19

patients.

METHODS

Data Search

We systematically searched the MEDLINE, medRxiv, PubMed, China Academic

Journals Full-text Database, Cochrane database and Web of Science database up till April

27, 2020, with no language restrictions taken into consideration. In addition, relevant

articles were also obtained from the reference list of reports which were identified using

this search strategy. The main key words included the following terms, "COVID-19",

"SARS-CoV-2" and "hydroxychloroquine".

Study Selection

Two reviewers reviewed 251 abstracts and 23 full-text articles independently. Our study

included only comparative studies that examined the efficacy or safety of

hydroxychloroquine with or without azithromycin in comparison with standard treatment

based on factors such as virological cure, degree of progression to severe illness and all-

cause mortality as identified in COVID-19 patients. Out of all the selected search material,

257 articles were excluded due to their inappropriate study design (review, editorial News

and letter). Among these, we also excluded a RCT as the results showed that 8 % (n=6)

of the patients assigned to hydroxychloroquine group did not receive any dose of

hydroxychloroquine and this might have caused misclassification bias in the study [22].

Quality Assessment

One reviewer extracted study-level data into standardized working tables, and the other

checked data accuracy. Two independent reviewers critically appraised the eligible

articles by using the Modified Downs and Black risk assessment scale [23]. This scale

consists of 27 items which assesses different study characteristics such as internal validity,

statistical power and external validity. Publication bias was also assessed by using a

funnel plot.

Data Synthesis and Statistical Analysis

The efficacy outcome of interest in this article was virological clearance and progression

of disease. The safety outcome which we planned to investigate through this review, was

mortality. We analyzed the main beneficial outcome based on the consistency and

availability of results which were reported across various recruited trials such as the level

of virological clearance noticed after the treatment, which was defined as a negative result

of SARS-COV-2 after detecting it by real-time reverse transcription-PCR. We performed

the meta-analysis by using Mantel Hazel method for dichotomous data. In our present

study, either fixed-effect model or random effect model was used according to the level

of heterogeneity. The odds ratio (OR) was used as the common measure of association

across studies. We assessed statistical heterogeneity through the I^2 index. Meta-analysis

was undertaken by using Cochrane Collaboration Review Manager (RevMan) software

version 5.3.

Subgroup Analysis

Subgroup analysis was carried out by including the clinical status (symptomatic or

asymptomatic) and age so as to assess the impact of these variables on outcome.

RESULTS

Description of Included Trials

After selecting the relevant articles we found five eligible comparative trials that focused on the benefits of hydroxychloroguine alone or in combination with azithromycin, for the treatment of COVID-19. There were a total of 677 participants, and each trial included in this research had sample size ranging from 30 to 368 [7-11]. Supplementary table 1 shows the main characteristics of the eligible studies included in the research. Follow-up duration of included trials ranged from 6 to 7 days. Among the included trials, two trials which were conducted in China studied hydroxychloroquine effect at a dose of 400 mg when given daily for 5 days [7, 9] and other French trial studied hydroxychloroquine outcome at a doses of 600 mg given daily with or without azithromycin (500 mg at day 1 and 250 mg at days 2 to 5) [8]. In addition, another French trial tested hydroxychloroguine effect when given at a dose of 600 mg daily [11] and another trial investigated benefits of hydroxychloroquine, with or without azithromycin but dosage was not mentioned in the research [10]. Among the five trials which were included, four trials mentioned their exclusion criteria as - the patients who had known allergy to hydroxychloroquine or any other known contraindication in terms of usage of the study drugs, such as retinopathy or

pregnancy [7-9, 11]. However, one trial was conducted without considering any exclusion

criteria [10] and where the average age of participants was reported to be 62.6 years.

Quality of Included Studies

The risk of bias assessment is reported in supplementary figure 1. The average Downs

and Black score was 19, with a range between 18 and 22 (A higher score indicates less

bias). Various studies have shown different degree of bias wherein the RCT conducted by

Chen et al. has displayed the lowest risk of bias [9] and the open-label non-RCT had

shown the highest risk of bias [8]. One Chinese trial was described as randomized,

although the method of randomization, allocation concealment and blinding of assessors

during outcome evaluation was not mentioned [7] whereas another randomized control

trial properly described the method of randomization and double-blinding [9]. With

regard to the study design, one French trial was designed as open-label non- randomized

trial [8] and two other studies were planned as controlled retrospective studies [10, 11].

A trial reported a loss of follow-up by participants while undergoing treatment hence they

were excluded during analysis planning due to their withdrawal from the study [8].

Effect on Antiviral Clearance

Antiviral clearance was calculated using results obtained from PCR which were

documented as SARS-CoV-2 carriage during the follow-up period after treatment was

over. For conducting the meta-analysis, we used one-time observation of negative results

seen in PCR which were carried forward during analysis. Two studies have reported

treatment effects based on antiviral clearance [7, 8].

Only two trials were included for meta-analysis, assessing a total of 66 participants. We

found no significant evidence to verify whether hydroxychloroquine with or without

azithromycin used for the treatment was effective in reducing viral carriage (OR 1.95

[95% CI 0.19 to 19.73]). There was substantial and statistically significant heterogeneity

present while conducting this analysis ($I^2 = 62\%$) (figure 2A). As for the treatment

undertaken by using hydroxychloroquine alone, the meta-analysis showed an increment

by 1.74 times as compared with control group (95% CI 0.51 to 5.91; $I^2 = 35\%$) while

evaluating the viral clearance (figure 2B).

One trial compared the effectiveness of combination therapy of hydroxychloroquine and

azithromycin with control group and the results indicated that there was a significant

reduction in viral load when combination therapy was used (OR 27.18 [95% CI 1.29 to

574.32]) (figure 2C) [8]. Based on intention-to-treat method, we also included 6 patients

in the research who did not follow up after the treatment was over during the French trial

[8]. The pooled analysis implied a trend that treatment by hydroxychloroquine with or

without azithromycin was effective in reducing viral load in Covid-19 patients (OR 1.72

[95% CI 0.26 to 11.50]; I^2 =49%) (figure 2D). A statistically significant reduction of the

viral carriage was noticed at D6-post inclusion while performing a French trial [8].

However, another trial conducted in Chinese patients indicated a shift towards favoring

the control group in reducing viral load at D7-post inclusion [7]. A Chinese study reported

that the use of hydroxychloroquine as compared to the control group where only standard

treatment was followed, could shorten clinical recovery time (TTCR) and promote

development of pneumonia (CT) [9].

Subgroups Analysis

Subgroup analysis was undertaken to explore the impact of different factors relating to

the context of the study that may influence the effectiveness of the intervention including,

clinical status and age.

Clinical status

A recent trial conducted by Gautret et al. which included 6 asymptomatic COVID-19

patients and 60 patients who showed symptoms of upper respiratory tract infection (URTI)

or lower respiratory tract infection (LRTI) [8]. Another trial conducted in China included

30 moderately affected COVID-19 patients who displayed symptoms such as fever or respiratory tract infection [7]. Subgroup analysis performed according to baseline clinical status of patients did not demonstrate any difference related to the effect of the intervention. A meta-analysis which included patients with symptomatic clinical status (e.g. URTI or LRTI) and had used hydroxychloroquine alone or in combination with azithromycin for treatment, showed no significant evidence in the effect of the viral elimination as seen by the value of odd's ratio (OR 3.33 [95% CI 0.08 to 146.36]; I^2 =80%) (supplementary figure 2A). Among the selected studies there were two studies that included symptomatic patients who used hydroxychloroquine monotherapy [7, 8]. When meta-analysis was conducted by including these two trials, no significant difference between intervention and control groups was seen, in addition substantial statistical heterogeneity was identified ($I^2 = 69\%$) (supplementary figure 2B). A meta-analysis has reported that in patients with symptomatic clinical status, usage of hydroxychloroquine along with azithromycin for treatment of COVID-19 has showed beneficial outcome with regard to seroconversion (OR 99.67 [95% CI 3.52 to 2818.12]) (supplementary figure 2C).

Age

Out of all the included trials in our present research, one trial [8] has included only adults

while the other trial [7] has included 4 participants younger than 18 years-old. To examine the treatment effects on adults, we excluded those 4 patients and conducted subgroup analysis. Data extracted from adult-specific subgroup analysis showed limited benefit of using hydroxychloroquine alone or in combination with azithromycin for the purpose of viral elimination (OR 3.59 [95% CI 0.07 to 183.82]; I^2 =82%) (supplementary figure 3A). The result also showed that there was no significant evidence that could support that hydroxychloroquine, when used without azithromycin for the treatment, was effective in reducing viral carriage in adults (OR 2.71 [95% CI 0.09 to 80.15]; I^2 =75%) (supplementary figure 3B). A pooled analysis of adult patients highlighted that using hydroxychloroquine plus azithromycin for the treatment showed significant benefits in promoting viral seroconversion (OR 99.67 [95% CI 3.52 to 2818.12]) (supplementary figure 3C).

Antiviral Effect of Hydroxychloroquine Monotherapy or Azithromycin-based

Combination Therapy

We conducted another meta-analysis to compare the antiviral effects of using hydroxychloroquine alone, or when combined with azithromycin and the results showed that there is an inclination of more benefits being detected with regard to reduction in viral load in the combination group (OR 9.94 [95% CI 0.47 to 210.41]) (figure 3).

Progression to Severe Illness

During the research period, progression to severe illness as seen in COVID-19 patients in association with the study drug was noticed in all the five included trials [7-11]. Although, quantitatively lower rate of progression to severe illness was reported in the hydroxychloroquine usage groups, whether with or without azithromycin combination, but there was no significant difference documented when compared with control groups (OR 0.89 [95% CI 0.58 to 1.37]; I^2 =30%) (figure 4A). We analyzed the efficacy of treatment in association with worsening of disease and the research findings showed a more favorable outcome in the study drug groups. (figure 4B and 4C).

All-cause Mortality

For analyzing all-cause mortality, we included three trials which had relevant results associated with regard to mortality [7, 8, 10]. The research findings concluded that hydroxychloroquine use, whether in combination with azithromycin or not, was associated with increased mortality in COVID-19 patients (figure 5A-C)

Death or Progression to Severe Illness

The overall pooled OR was 1.00 for death or progression to severe illness in patients

treated with hydroxychloroquine, with or without azithromycin versus control groups for four studies that had complete data regarding the same [7-9, 11] (95% CI 0.27-3.75, I^2 =33%) (figure 6A). However, the pooled OR was 1.37 when a comparison of hydroxychloroquine alone versus the control group was conducted (95% CI 0.09-21.97, I^2 =59%) (figure 6B).

Publication Bias

In total, five trials were included in the present study and were appropriately evaluated for publication bias by conducting funnel plot analysis. As shown in supplementary figure 4, there was no obvious publication bias reported.

DISCUSSION

To solve the COVID-19 pandemic, it is urgently required to find effective pharmacological agents. Hydroxychloroquine is a repositioning candidate, still with reports of unclear efficacy and safety issue when used for the treatment of COVID-19. Therefore, we conducted a systematic review and meta-analysis to address not only the efficacy and safety issue of hydroxychloroquine, but also to explore its efficacy when used in combination with azithromycin for treating COVID-19 patients. The present study yielded several important findings. Firstly, hydroxychloroquine might show benefits in virological clearance of SARS-CoV-2 and a reduction in the risk of disease progression, although no statistical significant findings were reported. Secondly, the combination therapy of hydroxychloroquine and azithromycin seems to show a synergistic effect. Thirdly, use of hydroxychloroquine was associated with an increased mortality. To the best of our knowledge, this study is the first systematic review and meta-analysis which has addressed the issue of combining hydroxychloroguine and azithromycin in COVID-19 patients, by summarizing available results extracted from clinical trials.

Our results have suggested that hydroxychloroquine use, whether in the form of monotherapy or combined with azithromycin, has shown a beneficial response in conversion of nucleic acid in COVID-19 patients as compared to the control groups.

Consistent findings were also noted in groups treated with hydroxychloroquine alone or groups where hydroxychloroquine and azithromycin-based combination therapy was used. While conducting subgroup analysis with regard to symptomatic and adult subpopulations, no statistically significant difference was found between drug treatment group and control group in terms of virological cure. These results were based on the outcome reported in only two trials which had their own limitations such as small sample size (66 patients), short observation period (6-7 days) and short duration of drug treatment (5-10 days) [7, 8]. Another small case series which included more severely infected COVID-19 patients reported an unfavorable viral elimination with the combined use of hydroxychloroquine and azithromycin [13]. However, Gautret et al. conducted a similar study which included 80 patients and reported that hydroxychloroquine when coadministered with azithromycin displayed a prompt reduction in viral load, with nearly 80-90% negative cases reported at Day7-8 [12]. Another cohort study which took place in France, included 1061 new COVID-19 patients who were treated with hydroxychloroquine and azithromycin. The study results showed excellent clinical outcome and virological cure in 973 patients on day 10 (91.7%) with death reported in few patients (0.75%) [15]. A study which was conducted in Iraq reported that 79 patients were treated with a protocol which included hydroxychloroquine and other antiviral drugs for dealing with diverse COVID-19 categories, showed a promising rate of complete clinical recovery [14]. In the present study, we found that hydroxychloroquine monotherapy might decrease COVID-19 patients' progression to worse illness but without any reports of statistical significance. Although our results showed higher rate of viral elimination and lower rate of disease worsening in patients treated with combination of hydroxychloroquine and azithromycin, there was no significant difference in the outcome when compared with control groups.

The anti-inflammatory effect of hydroxychloroquine on the immune system has been well recognized. The antiviral mechanisms of hydroxychloroquine in treating COVID-19 patients has also been discovered, including increasing pH values of endosomes or lysosomes, stopping the glycosylation of angiotensin converting enzyme (ACE) 2 receptor, inhibiting antigen processing and following major histocompatibility complex (MHC)-II presentation to T cells and interrupting the interaction between cytosolic viral DNA/RNA and toll-like receptors (TLRs) [24, 25]. Azithromycin, a member of the macrolide family, has antibacterial, anti-inflammatory, and antiviral properties [26, 27]. Although azithromycin has been found to block influenza virus internalization into host cells, its mechanism of action against SARS-CoV-2 is still uncertain [28]. Regarding the antiviral effects of using combination of hydroxychloroquine and azithromycin, Andreani et al. demonstrated that such combination showed a synergistic effect against SARS-CoV-

2 when research was conducted in vitro [29].

effect [30, 31].

In terms of safety issue, two RCT trials and one case series reported mild adverse effects such as rash and diarrhea among patients [7, 9, 11]. One comparative study which has used hydroxychloroquine alone, found that 9.5% of patients experienced ECG change, leading to its discontinuation [11]. Another case series which was conducted in France, involving 11 patients reported that one patient developed QT prolongation [13]. Chorin et al. also found that 11% of patient receiving combination therapy (hydroxychloroquine and azithromycin) suffered from severe QT prolongation (>300 milliseconds) [16]. Notably, reports have suggested that both azithromycin and hydroxychloroquine are associated with QT prolongation, and their combined use may potentiate this adverse

In addition, we found that the incidence of mortality favored control group rather than the use of hydroxychloroquine with or without azithromycin as demonstrated with an OR of 2.54 in the pooled analysis. Most of the included trials had small sample size which might have impacted the significance of our results [8, 9]. Among the included studies, one of them investigated by Magagnoli et al. had few findings which were different from the rest. Here, subjects with contraindication to usage of hydroxychloroquine or had

significant comorbidities were not excluded from the patients population, comprised only men whose median age was over 65 years, and majorly who were non-Hispanic black [10]. Reports have indicated that the average age of COVID-19 patients was about 50 years, and the percentage distribution among male and female was nearly equal [30-32] Since the mortality risk for COVID-19 varies by age, the current evidence suggests that older people are at a higher risk of getting affected from COVID-19 than younger ones [33, 34] and it might be related to multiple comorbidities commonly seen in older people [35]. Higher rates of COVID-19 -related hospitalization among the elder population and non-Hispanic black have also been found in the United States [36]. The mortality rate in different countries might be also associated with socio-economic and political factors [37]. Therefore, our present results of pooled analysis might be biased as we also included the demographic composition of patients, mentioned in the study conducted by Magagnoli et al.

Despite the pertinent information demonstrated above, our systematic review has its own limitations. As far as the lack of compiling sufficient data with regard to virological cure as efficacy outcome is concerned, we tried to solve this problem by conducting a search for unpublished literature and non-English journals to increase the quantity of relevant integrated literature.. Most studies which are published are mainly observational studies

and case series with substantial methodology concerns such as no framework of exclusion criteria, and therefore susceptible to bias and confounding. Therefore, as there are limited related RCTs in the literature at present, only those were included in our study. In the lack of experimental random allocation to the intervention, the effects of the hydroxychloroquine might be overestimated. Furthermore, the two single-center RCTs which were conducted in China had some limitations as it included small sample size, did not conduct an international trial, and only limited data was available regarding the viral load. In our present study, bias might be present since little information was provided on demographic data, comorbidity, severity of disease, and the adverse effects of hydroxychloroquine or azithromycin such as QT prolongation. In addition, we have not performed a dose–response meta-analysis, due to the lack of original data. Finally, the limited number of available studies which were included, made it unworkable to evaluate the true effect of hydroxychloroguine. Therefore, the present results should be interpreted cautiously, and further large, prospective RCTs needs to be conducted in a methodologically rigorous manner.

CONCLUSION

The present study has suggested that hydroxychloroquine alone, or in combination with azithromycin for COVID-19 treatment showed beneficial outcome but also higher

mortality. The combination of hydroxychloroquine and azithromycin has demonstrated synergistic effects. In future, large, randomized, placebo-controlled trials with longer

ACKNOWLEDGMENTS

follow-up are needed to further confirm these findings.

None.

DISCLOSURES

None.

FUNDING

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported partly by Taipei Veterans General Hospital (V109EA-014, VGH-2017/2020 C and E project).

REFERENCES

- 1. Steven S, Yen Ting L, Chonggang X, et al. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis* 2020: 26(7).
- 2. Worldometers. COVID-19 coronavirus pandemic. 2020: Available from: https://www.worldometers.info/coronavirus/.
- 3. Wang X, Xu W, Hu G, et al. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. *Cell Mol Immunol* 2020.
- 4. Colson P, Rolain J, Lagier J, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. *Int J Antimicrob Agents* 2020: 55(4): 105932.
- 5. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis* 2020.
- 6. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell discovery* 2020: 6: 16.
- 7. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). *J Zhejiang Univ (Med Sci)* 2020: Published online March 6, 2020. doi:10.3785/j.issn.1008-9292.2020.03.03.
- 8. Gautret P, Lagier J, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents* 2020: Published online March 20, 2020. doi:10.1016/j. ijantimicag.2020.105949: 105949.
- 9. Chen Z, Hu H, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv* 2020: preprint. [https://doi.org/10.1101/2020.1103.1122.20040758].
- 10. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. *medRxiv* 2020: preprint. [https://doi.org/10.1101/2020.1104.1116.20065920].
- 11. Mahevas M, Tran V, Roumier M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. *medRxiv* 2020: preprint. [https://doi.org/10.1101/2020.1104.1110.20060699].
- 12. Gautret P, Lagier J, Parola P, et al. Clinical and microbiological effect of a

- combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. *Travel Med Infect Dis* 2020: 101663.
- 13. Molina J, Delaugerre C, Le Goff J, et al. No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection. *Med Mal Infect* 2020.
- 14. Allawi J, Abbas H, Rasheed J, et al. The first 40-days experience and clinical outcomes in the management of coronavirus covid-19 crisis. Single center preliminary study. *Journal of the Faculty of Medicine Baghdad* 2020: 61(3,4): https://doi.org/10.32007/j fac med bagdad.% y.32613,32004% p.
- 15. Million M, Lagier J-C, Gautret P, et al. Full-length title: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. *Travel Med Infect Dis* 2020: 101738.
- 16. Chorin E, Dai M, Shulman E, et al. The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin. *medRxiv* 2020: preprint. [https://doi.org/10.1101/2020.1104.1102.20047050].
- 17. Gbinigie K, Frie K. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. *BJGP Open* 2020: bjgpopen20X101069.
- 18. Singh A, Singh A, Shaikh A, et al. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. *Diabetes Metab Syndr* 2020: 14(3): 241-246.
- 19. Kapoor K, Kapoor A. Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19 Infection- A Systematic Literature Review. *medRxiv* 2020: preprint. [https://doi.org/10.1101/2020.1103.1124.20042366].
- 20. Sarma P, Kaur H, Kumar H, et al. Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis. *J Med Virol* 2020.
- 21. Shamshirian A, Hessami A, Heydari K, et al. Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis. *medRxiv* 2020: preprint. [https://doi.org/10.1101/2020.1104.1114.20065276].
- 22. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. *medRxiv* 2020: preprint. [https://doi.org/10.1101/2020.1104.1110.20060558].
- 23. Downs S, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health* 1998: 52(6): 377-384.

- 24. Alia E, Grant-Kels JM. Does Hydroxychloroquine Combat COVID-19? A Timeline of Evidence. *J Am Acad Dermatol* 2020.
- 25. Sinha N, Balayla G. Hydroxychloroquine and covid-19. *Postgrad Med J* 2020.
- 26. Schogler A, Kopf BS, Edwards MR, et al. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. *Eur Respir J* 2015: 45(2): 428-439.
- 27. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. *Eur Respir J* 2010: 36(3): 646-654.
- 28. Ohe M, Shida H, Jodo S, et al. Macrolide treatment for COVID-19: Will this be the way forward? *Biosci Trends* 2020.
- 29. Andreani J, Le Bideau M, Duflot I, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. *Microb Pathog* 2020: 145: 104228.
- 30. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA cardiology* 2020.
- 31. Bessiere F, Roccia H, Deliniere A, et al. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. *JAMA cardiology* 2020.
- 32. Wu J, Liu J, Zhao X, et al. Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. *Clin Infect Dis* 2020.
- 33. Zhai P, Ding Y, Wu X, et al. The epidemiology, diagnosis and treatment of COVID-19. *Int J Antimicrob Agents* 2020: 105955.
- 34. ChinaCDC. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. *Zhonghua Liu Xing Bing Xue Za Zhi* 2020: 41(2): 145-151.
- 35. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020: 395(10229): 1054-1062.
- 36. Garg S, Kim L, Whitaker M. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 COVIDNET, 14 States, March 1–30, 2020. *MMWR Morb Mortal Wkly Rep* 2020(69): 458–464.
- 37. Sorci G, Faivre B, Morand S. Why does COVID-19 case fatality rate vary among

countries? medRxiv 2020: preprint.

 $[\underline{https://doi.org/10.1101/2020.1104.1117.20069393}].$




Figure 1. Prisma flow chart of included studies





Figure 2. Seroconversion of SARS-CoV-2. (HCQ \pm AZI: hydroxychloroquine with or without azithromycin; HCQ + AZI: combination of hydroxychloroquine and azithromycin)

Figure 3. Seroconversion of SARS-CoV-2 (Hydroxychloroquine plus azithromycin versus hydroxychloroquine alone).



- (1) We included all HCQ treated patients using intention-to-treat method (20 HCQ with or without AZI + 6 lost to follow up)
- (2) Outcomes based on pre-ventilation treatment
- (3) Disease progression was defined as acute respiratory distress syndrome on day 7 (using weighted proportion data)

(B) Progression to severe illness (HCQ alone vs. control)

	HCQ	Control		Odds Ratio		Odds Ratio		
Study or Subgroup	Events Tot	al Events Tota	Weight	M-H, Fixed, 95% C	I M-H	I, Fixed, 95%	CI	
Chen J 2020	1 1	5 0 15	2.3%	3.21 [0.12, 85.20]		- •		
Chen Z 2020	0 3	1 4 31	22.2%	0.10 [0.00, 1.88]	•			
Gautret P 2020 (1)	3 2	0 0 16	2.3%	6.60 [0.32, 137.78]	•		•	\longrightarrow
Magagnoli J 2020 (2)	12 9	0 25 177	73.2%	0.94 [0.45, 1.96]		_		
Total (95% CI)	15	6 239	100.0%	0.93 [0.49, 1.76]		*		
Total events	16	29						
Heterogeneity: Chi ² = 4	.38, df = 3 (P =	0.22); I ² = 31%			0.01 0.1	+	10	100
Test for overall effect: Z	2 = 0.22 (P = 0	83)				HCQ Favour		100

- Footnotes
 (1) We included all HCQ treated patients using intention-to-treat method (14 HCQ + 6 lost to follow up)
- (2) Outcomes based on pre-ventilation treatment

(C) Progression to severe illness (HCQ + AZI vs. control)

	HCQ +	AZI	Conti	rol		Odds Ratio			Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	<u> </u>	M-H,	Random, 9	5% CI	
Gautret P 2020	0	6	0	16		Not estimable			_		
Magagnoli J 2020 (1)	7	101	25	177	100.0%	0.45 [0.19, 1.09]					
Total (95% CI)		107		193	100.0%	0.45 [0.19, 1.09]		4	•		
Total events	7		25								
Heterogeneity: Not appl							0.01	0.1	1	10	100
Test for overall effect: Z	= 1.77 (P	9 = 0.08	3)						+ AZI Favo		100

Footnotes (1) Outcomes based on pre-ventilation treatment

Figure 4. Progression to severe illness.

(A) All-cause mortality (HCQ ± AZI vs. control)

	HCQ ± AZI	Control		Odds Ratio	Odds Ratio
Study or Subgroup	Events Total	al Events To	otal Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Chen J 2020	0 1	5 0	15	Not estimable	
Gautret P 2020 (1)	1 2	6 0	16 3.6%	1.94 [0.07, 50.56]	
Magagnoli J 2020	52 21	0 18	158 96.4%	2.56 [1.43, 4.58]	
Total (95% CI)	25	1 .	189 100.0%	2.54 [1.43, 4.50]	•
Total events	53	18			
Heterogeneity: Chi ² = 0	0.03, df = 1 (P =	= 0.87); I ² = 0%	%		0.01 0.1 1 10 100
Test for overall effect:	Z = 3.18 (P = 0	.001)			Favours HCQ ± AZI Favours control

Footnotes
(1) We included all HCQ treated patients using intention-to-treat method (20 HCQ with or without AZI + 6 lost to follow up)

(B) All-cause mortality (HCQ alone vs. control)

	HCQ	Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events Tol	al Events	Total	Weight	M-H, Fixed, 95% C	CI M-H, Fixed, 95% CI
Chen J 2020	0	15 0	15		Not estimable	e
Gautret P 2020 (1)	1 :	20 0	16	4.9%	2.54 [0.10, 66.59]	9]
Magagnoli J 2020 (2)	27	97 18	158	95.1%	3.00 [1.55, 5.81]	1]
Total (95% CI)	13	32	189	100.0%	2.98 [1.56, 5.70]	n
Total events	28	18				
Heterogeneity: Chi ² = 0	.01, df = 1 (P	= 0.92); I ² =	0%			0.01 0.1 1 10 100
Test for overall effect: Z	= 3.29 (P = 0)	.0010)				Favours HCQ Favours control

- (1) We included all HCQ treated patients using intention-to-treat method (14 HCQ + 6 lost to follow up)
- (2) Outcomes based on treatment exposure

(C) All-cause mortality (HCQ + AZI vs. control)

	HÇQ +	AZI	Conti	rol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Gautret P 2020	0	6	0	16		Not estimable	_
Magagnoli J 2020 (1)	25	113	18	158	100.0%	2.21 [1.14, 4.28]	-
Total (95% CI)		119		174	100.0%	2.21 [1.14, 4.28]	•
Total events	25		18				
Heterogeneity: Not app							0.01 0.1 1 10 100
Test for overall effect: Z	: = 2.35 (F	P = 0.02	2)				Favours HCQ + AZI Favours control

Figure 5. All-cause mortality.

Footnotes (1) Outcomes based on treatment exposure

(A) Death or clinical worsening of disease (HCQ \pm AZI vs. control)

	HCQ ±	AZI	contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H. Random, 95% CI
Chen J 2020	1	15	0	15	13.1%	3.21 [0.12, 85.20]	-
Chen Z 2020	0	31	4	31	15.4%	0.10 [0.00, 1.88]	•
Gautret P 2020 (1)	4	26	0	16	15.2%	6.60 [0.33, 131.25]	
Mahevas M 2020 (2)	16	84	19	89	56.3%	0.87 [0.41, 1.82]	- - -
Total (95% CI)		156		151	100.0%	1.00 [0.27, 3.75]	—
Total events	21		23				
Heterogeneity: Tau ² = 0	0.66; Chi ² =	= 4.46,	df = 3 (P	= 0.22); I ² = 33%)	0.01 0.1 1 10 100
Test for overall effect: 2	Z = 0.00 (P)	= 1.00))				0.01

(B) Death or clinical worsening of disease (HCQ alone vs. control)

	HCC	Q	Conti	rol		Odds Ratio		Odds	s Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rand	dom, 95% CI	
Chen J 2020	1	15	0	15	31.6%	3.21 [0.12, 85.20]			•	
Chen Z 2020	0	31	4	31	34.4%	0.10 [0.00, 1.88]	←	•	 	
Gautret P 2020 (1)	4	20	0	16	34.0%	9.00 [0.45, 180.84]		_	•	→
Total (95% CI)		66		62	100.0%	1.37 [0.09, 21.97]		-		
Total events	5		4							
Heterogeneity: $Tau^2 = 3.54$; $Chi^2 = 4.87$, $df = 2$ (P = 0.09); $I^2 = 59\%$							0.01	0.1	1 10	100
Test for overall effect:	Z = 0.22 (P = 0.8	2)				0.01		Favours control	100

Figure 6. Death or clinical worsening of disease.

⁽¹⁾ We included all HCQ treated patients using intention-to-treat method (20 HCQ with or without AZI + 6 lost to follow up) (2) Use weighted proportion data

Footnotes
(1) We included all HCQ treated patients using intention-to-treat method (14 HCQ + 6 lost to follow up)